Are We Ready for Adjuvant Sunitinib in High-risk Renal Cell Carcinoma?
Author:
Publisher
Elsevier BV
Subject
Urology
Reference10 articles.
1. Renal cell carcinoma;Hsieh;Nat Rev Dis Primers,2017
2. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease;Janzen;Urol Clin N Am,2003
3. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial;Haas;Lancet,2016
4. Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial;Haas;JAMA Oncol,2017
5. Motzer RJ, Haas NB, Donskov F, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol. In press. http://dx.doi.org/10.1200/JCO.2017.73.5324.
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Adjuvant therapy for renal cell carcinoma: Finding the signal in the noise;Urologic Oncology: Seminars and Original Investigations;2024-07
2. Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma;Expert Review of Anticancer Therapy;2019-02-04
3. Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis;European Urology;2018-11
4. Contemporary Trends in Adjuvant and Neoadjuvant Treatment for Renal Cell Carcinoma;The Bulletin of Urooncology;2018-09-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3